Redesigned Cell-Penetrating Peptide Uses a Smart Cleavable Link to Deliver Gene-Silencing RNA into Cancer Cells | Research

The takeaway

Adding a sterically refined disulfide linker to a bifunctional cell-penetrating peptide enabled efficient intracellular delivery of siRNA by allowing the peptide to activate specifically inside the reductive environment of cancer cells.

Efficient cytosolic delivery achieved
The sterically refined disulfide linker overcame the endosomal trapping problem that plagued the previous design, enabling siRNA to reach the cytosol where it can silence target genes.

What the researchers found

The researchers developed PI-linker-cRGD, a prodrug-type bifunctional cell-penetrating peptide with a sterically refined redox-cleavable disulfide linker connecting the membrane-penetrating PI peptide to the cancer-targeting cRGD ligand.

The previous version (PI-cRGD) achieved cellular uptake via endocytosis but failed to deliver siRNA to the cytosol because steric hindrance prevented disulfide bond cleavage inside cells. The redesigned linker solved this problem: it allowed thiol-disulfide exchange at the cell surface, activating the CPP to promote membrane translocation and achieving efficient cytosolic siRNA delivery while maintaining low cytotoxicity and cancer-targeting ability.

Why it matters

siRNA therapeutics have enormous potential for treating cancer and genetic diseases by silencing specific genes, but getting them inside cells remains one of the biggest hurdles. Cell-penetrating peptides are a leading delivery strategy, and this work shows that small chemical modifications to the linker connecting functional peptide domains can make the difference between a system that traps cargo in endosomes and one that successfully delivers it to the cytosol where it needs to work.

How the study worked

The researchers synthesized a modified bifunctional cell-penetrating peptide with an optimized disulfide linker between the PI (membrane-permeable amphipathic helical peptide containing Aib residues) and cRGD (αvβ3 integrin-targeting) domains. siRNA complexes were formed and tested in cancer cell lines for cellular uptake, cytotoxicity, disulfide cleavage, and cytosolic siRNA delivery efficiency.

What this study cannot tell us

This was an in vitro study using cancer cell lines only. The efficiency of the disulfide cleavage mechanism in vivo, where the redox environment is more complex, is unknown. Biodistribution, pharmacokinetics, and off-target effects in animal models have not been evaluated. The specific siRNA target and knockdown efficiency were not quantified in the abstract. Scalability of the peptide conjugate synthesis for therapeutic production is not discussed.

How to read the evidence

This is a preclinical proof-of-concept study demonstrating a chemical design improvement for peptide-based drug delivery. The evidence is at the earliest stage — in vitro cell line experiments with no animal or human data.

When this study was published

Published in 2025, this is very recent work in the rapidly evolving field of peptide-based intracellular delivery. The redox-cleavable linker strategy is currently being explored by multiple research groups.

The bigger picture

Cell-penetrating peptides have been studied for decades as drug delivery vehicles, but translating their promise into clinical reality has been hindered by challenges like endosomal trapping — where the delivery vehicle gets into the cell but the cargo remains stuck in membrane-bound compartments. This study's linker optimization approach addresses that fundamental bottleneck. The principle of using redox-responsive cleavable linkers is broadly applicable to other peptide-drug conjugates and could accelerate the development of peptide-based delivery systems for RNA therapeutics.

Questions still open

Does the redox-cleavable linker strategy maintain its efficiency in animal tumor models where the extracellular redox environment differs from cell culture?
Could this linker approach be applied to deliver other therapeutic cargoes beyond siRNA, such as mRNA or antisense oligonucleotides?
How does the gene silencing efficiency of this CPP-siRNA system compare to lipid nanoparticle-based siRNA delivery platforms?

Common questions

What is a cell-penetrating peptide and why is it needed for siRNA delivery?

Cell-penetrating peptides are short amino acid sequences that can cross cell membranes — something most molecules, including siRNA, cannot do on their own. By attaching siRNA to a cell-penetrating peptide, researchers can shuttle the gene-silencing molecule past the cell membrane and into the interior where it needs to work.

What was the problem with the original design and how was it fixed?

The original peptide got siRNA into cells but it remained trapped in membrane-bound compartments (endosomes) instead of reaching the cytosol. This happened because the disulfide bond connecting the two functional parts was too bulky to be cleaved inside cells. By redesigning the linker to be less sterically hindered, the bond could break at the cell surface, freeing the membrane-penetrating peptide to carry siRNA into the cytosol.

Read the original research

Redox-cleavable disulfide linker enhances siRNA delivery by prodrug-type bifunctional cell-penetrating peptide.

Bioorganic & medicinal chemistry, 130, 118383

View on PubMed ↗Publisher’s paper ↗

Citation

Wakamori, Keita; Hashikawa, Yuzuki; Urata, Hidehito; Wada, Shun-Ichi. (2025). Redox-cleavable disulfide linker enhances siRNA delivery by prodrug-type bifunctional cell-penetrating peptide.. Bioorganic & medicinal chemistry, 130, 118383. https://doi.org/10.1016/j.bmc.2025.118383